← All trials
NCT05824390
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2020
- Primary completion
- Oct 1, 2023
- Completion date
- Oct 1, 2023
- First posted
- Apr 21, 2023
- Last posted
- Apr 21, 2023
- Enrollment
- 116
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Zhejiang UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversitySponsor investigator
- Sun Yat-Sen UniversityCollaborator
- Ningxia Medical UniversityCollaborator
- Ningbo Yinzhou People's HospitalCollaborator
- Xiamen Hongai HospitalCollaborator
- Tongji UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.